The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Patients as Drivers: A Prescription for the Future

It's a different world than when I was diagnosed in 1996 with the incurable cancer multiple myeloma. Today, thanks to advances in sequencing technologies, we have gained unprecedented insights into the genetic drivers of cancer. We now have an arsenal of breakthrough treatments that take into account these genetics and patients' other unique characteristics, personalizing care and giving patients their very best chance of beating the odds. And, with access to information with the click of a mouse or swipe on a smartphone and the increasing availability of digitized health records, patients now find themselves as vital partners not only in their care, but also in the research process itself - a position that has the power to transform the landscape more than we can even imagine. READ MORE

Posted: November 04, 2015

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy.

Sponaas AM, Moharrami NN, Feyzi E, Standal T, Holth Rustad E, Waage A, Sundan A. PLoS One. 2015 Oct 7;10(10):e0139867. doi: 10.1371/journal.pone.0139867. eCollection 2015. PMID: 26444869 [PubMed - in process] READ MORE

Posted: October 22, 2015

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.

Canella A, Nieves HC, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. Oncotarget. 2015 Sep 25. [Epub ahead of print] PMID: 26429859 [PubMed - as supplied by publisher] READ MORE

Posted: October 22, 2015

Page 42 of 87« First...102030...4041424344...506070...Last »